FGF23 and chronic kidney disease: Clinical and laboratory findings have revealed novel insights into the pathomechanisms of CKD and the establishment of a feed-forward cycle promoting the dysregulation between factors has led to the identification of novel therapeutic opportunities, such as targeting non-canonical FGF23-mediated signaling.